Extract
In a recent issue of the journal, Bayet al. reported fifteen patients with anti–melanoma differentiation–associated protein 5 (anti-MDA5+) rapidly progressive interstitial lung disease (RP-ILD) requiring Bayextracorporeal life support (ECLS) [1]. In five patients, ECLS implementation allowing a bridge to emergency lung transplantation within a median delay of 8 days led to survival whereas in the ten others, fatal outcome occurred since no lung transplantation was possible, either in the absence of listing for transplantation by the medical team in charge or due to disqualification related to underlying morbidities.
Footnotes
This manuscript has recently been accepted for publication in theEuropean Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theERJonline. Please open or download the PDF to view this article.
Conflict of interest: Cloé Comarmond has nothing to disclose.
Conflict of interest: Bruno Mégarbane has nothing to disclose.
- ReceivedNovember 17, 2021.
- AcceptedApril 28, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contactpermissions{at}ersnet.org